Filing Details

Accession Number:
0001209191-18-053847
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-10-03 16:42:02
Reporting Period:
2018-08-21
Accepted Time:
2018-10-03 16:42:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1411690 Bionano Genomics Inc BNGO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1189124 L David Barker C/O Bionano Genomics, Inc.
9640 Towne Centre Drive, Suite 100
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-08-21 3,894 $6.47 3,894 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Warrants (right to buy) Acquisiton 2018-08-21 3,894 $6.47 3,894 $6.47
Common Stock Stock Option (Right to Buy) Acquisiton 2018-10-01 10,516 $0.00 10,516 $7.77
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,894 2023-08-21 No 4 P Direct
10,516 2028-09-30 No 4 A Direct
Footnotes
  1. The price reported in column 4 is a weighted average price. These units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, were purchased in multiple transactions at prices ranging from $6.37 to $6.4971, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of units purchased at each separate price within the ranges set forth herein.Units purchased at a price of $6.47 per unit, .
  2. September 21, 2018 or such earlier date as Roth Capital Partners LLC, as representative of the underwriters in the Company's Initial Public Offering, shall determine.
  3. The shares subject to the option shall vest monthly over 36 months beginning on the one-month anniversary of October 1, 2018 (the "Vesting Commencement Date") such that the option shall be fully vested and exercisable on the three year anniversary of the Vesting Commencement Date.